Compare CVS Health Corp (CVS) vs Synchrony Financial (SYF) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
CVS Health Corp vs Synchrony Financial — how do they compare? CVS Health Corp trades at $86.81 (market cap $112.29B), while Synchrony Financial trades at $72.93 (market cap $23.99B). The key difference: CVS Health Corp is far larger — about 4.7× Synchrony Financial's market cap, and CVS Health Corp pays the higher dividend (3.03%). Which is the better fit depends on your goals — on Pluang, investors hold CVS Health Corp for 83 Days and Synchrony Financial for 28 Days on average.
| CVS | SYF | |
|---|---|---|
Market Cap | $112.29B | $23.99B |
Volume | 7,763,676 | 3,813,027 |
Sector | Health | Financials |
52-Week High | $110.60 | $88.47 |
52-Week Low | $70.08 | $63.78 |
Typical Hold Time | 83 Days | 28 Days |
Enterprise Value | $174.64B | $24.23B |
Dividend Yield | 3.03% | 1.84% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CVS Health trades at $87.12, down 0.94% on the day, with strong analyst support showing 85% buy ratings and a $111.20 consensus price target. The stock demonstrates solid revenue growth, reaching $402.07 billion in 2025, though net margins compressed to 1.18%. Recent quarterly earnings have consistently beaten expectations, with Q2 2026 EPS of $2.58 surpassing the $1.85 forecast. Technical indicators show a bearish trend with key support at $85.
CVS presents a compelling value opportunity with attractive valuation ratios (P/E 23.17, P/S 0.27) and consistent dividend payments. However, declining profit margins and ongoing regulatory scrutiny pose risks. The company's Medicare expansion and healthcare services growth provide upside potential, but investors should monitor reimbursement pressures and competitive dynamics in the evolving healthcare landscape.
Synchrony Financial (SYF) trades at $73.16, up 1.71% on the day, with a bullish technical signal despite some bearish moving averages. The stock shows strong fundamentals, with a low P/E of 7.56 and robust profitability, including a 23.4% net income margin and 22.23% ROE. Recent earnings have consistently beaten expectations, and the company is expanding through partnerships like the recent tie-up with Vetspire and OpenAI.
The outlook is positive, supported by analyst consensus with a $87.58 price target and 61% buy ratings. Key opportunities include high receivables growth and strategic AI integrations, while risks involve increased investing cash outflows and potential consumer credit stress amid economic uncertainty.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About CVS Health Corp
Following its acquisition of Aetna in late 2018, CVS Health now provides an even more integrated healthcare-services offering for its members. Legacy CVS combined both the largest pharmacy benefit manager, processing over 2 billion adjusted claims annually, and a sizable pharmacy operation, including nearly 10,000 retail pharmacy locations primarily in the U.S. Adding a managed-care organization with 24 million medical members gives the company a strong position in the insurance industry and should help CVS better control overall healthcare costs for its clients.
Read more on CVS →About Synchrony Financial
Synchrony Financial is a premier consumer financial services company and the largest provider of private-label credit cards in the United States. Spun off from GE Capital in 2014, it operates through a unique B2B2C model, embedding its financing products within the ecosystems of major partners like Amazon, Lowe’s, and PayPal. Synchrony leverages deep data analytics and a diverse multi-platform strategy—spanning retail, health, and auto—to drive customer loyalty and provide specialized credit solutions at the point of sale.
Read more on SYF →
